Home / Combinations / AOD-9604 + Tirzepatide
AOD-9604 + Tirzepatide
Advanced Body Composition
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
Stack components
What each compound is researched for on its own. Nothing here describes an interaction between them.
Tirzepatide
Dual GIP/GLP-1 receptor agonist researched for significant appetite reduction, caloric intake suppression, and metabolic regulation contributing to body weight reduction.
AOD-9604
C-terminal hGH fragment (176–191) researched for stimulating lipolysis and inhibiting lipogenesis without affecting insulin sensitivity or promoting growth-related systemic effects.
Tirzepatide carries a well-characterized gastrointestinal side-effect profile in clinical research, including nausea and appetite suppression. AOD-9604 is generally reported as well-tolerated in Phase II human trials. No formal combination safety or efficacy data exists.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 23 Apr 2026.